Skip to main navigation Skip to search Skip to main content

New methoxy-chroman derivatives, 4[N-(5-methoxy-chroman-3-yl)N- propylamino]butyl-8-azaspiro-(4,5)-decane-7,9-dione [(±)-S 20244] and its enantiomers, (+)-S 20499 and (-)-S 20500, with potent agonist properties at central 5-hydroxytryptamine(1A) receptors

  • E. J. Kidd
  • , S. Haj-Dahmane
  • , T. Jolas
  • , L. Lanfumey
  • , C. M. Fattaccini
  • , B. Guardiola- Lemaitre
  • , H. Gozlan
  • , M. Hamon
  • Sorbonne Université

Research output: Contribution to journalArticlepeer-review

45 Scopus citations

Abstract

The potential interaction of the new methoxy-chroman derivatives: (±)-S 20244 (4-[N-(5-methoxy-chroman-3-yl)N-propylamino]butyl-8-azaspiro-( 4,5)- decane-7,9-dione) and its enantiomers (+)-S 20499 and (-)-S 20500 with central 5-hydroxytryptamine(1A) (5-HT(1A)) receptors was assessed using biochemical and electrophysiological tests in the rat. In vitro binding assays revealed that these drugs bound with high affinity to 5-HT(1A) sites in hippocampal membranes (K(i), 0.19 nM for (+)-S 20499, 0.95 nM for (-)-S 20500 and 0.35 nM for the racemate (±) S 20244). As seen with the prototypical 5-HT(1A) agonist 8-hydroxy-2-(di-n-propylamino)tetralin, (±)-S 20244, (+)-S 20499 and (-)-S 20500 inhibited forskolin-activated adenylate cyclase in hippocampal homogenates with potencies corresponding to their respective affinities for 5-HT(1A) sites. The maximal inhibitory effect of the chroman derivatives was not additive with that of 8-hydroxy-2-(di-n- propylamino)tetralin and could be competitively reduced by 5-HT(1A) antagonists such as (-)-propranolol and (±)-tertatolol. Electrophysiological recordings within the dorsal raphe nucleus both in vitro (in brain-stem slices) and in vivo (in chloral hydrate anesthetized rats) showed that (+)-S 20499, (±)-S 20244 and (-)-S 20500 induced, in that order of (decreasing) potency, a dose-dependent reduction in the spontaneous firing of serotoninergic neurons. In vitro, as well as in vivo, the inhibitory influence of the chroman derivatives on the discharge frequency of serotoninergic neurons could be competitively antagonized by (±)-tertatolol. Finally, oral administration of increasing doses of the most potent enantiomer, (+)-S 20499, induced a marked reduction in the rate of 5-HT turnover, without affecting that of dopamine, in various brain areas. All these biochemical and electrophysiological data indicate that (+)-S 20499 is a highly potent agonist at both presynaptic (i.e., somatodendritic) and postsynaptic 5-HT(1A) receptors in the rat brain.

Original languageEnglish
Pages (from-to)863-872
Number of pages10
JournalJournal of Pharmacology and Experimental Therapeutics
Volume264
Issue number2
DOIs
StatePublished - 1993

Fingerprint

Dive into the research topics of 'New methoxy-chroman derivatives, 4[N-(5-methoxy-chroman-3-yl)N- propylamino]butyl-8-azaspiro-(4,5)-decane-7,9-dione [(±)-S 20244] and its enantiomers, (+)-S 20499 and (-)-S 20500, with potent agonist properties at central 5-hydroxytryptamine(1A) receptors'. Together they form a unique fingerprint.

Cite this